Fulfilling unmet medical needs in antibiotic therapy

A considerable gap exists in modern antibiotic therapy. In hospitals, traditional means of antibiotic therapy rely on extremely expensive brand-name drugs that can effectively combat severe infections. At the other end of the spectrum, minor outpatient infections are being treated by cheap, generic antibiotic therapies that are being rendered useless as antibiotic resistance grows. What’s more, most major pharmaceutical companies are avoiding investing in the research and development of new antibiotic therapies, choosing to focus their efforts on developing new drug classes instead.

MiddleBrook Pharmaceuticals, Inc. has set out to bridge the considerable gap that exists in current antibiotic therapy. Our novel pulsatile dosing approach to antibiotic therapy, backed by our proprietary PULSYS™ drug delivery technology, holds the potential to be more effective, more efficient, more convenient, and less likely to induce resistance than any antibiotic therapy employed today.